1. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial. Issue 3 (March 2023) Authors: Tolaney, Sara M; Tarantino, Paolo; Graham, Noah; Tayob, Nabihah; Parè, Laia; Villacampa, Guillermo; Dang, Chau T; Yardley, Denise A; Moy, Beverly; Marcom, P Kelly; Albain, Kathy S; Rugo, Hope S; Ellis, Matthew J; Shapira, Iuliana; Wolff, Antonio C; Carey, Lisa A; Barroso-Sousa, Romualdo; Villagra... Journal: Lancet oncology Issue: Volume 24:Issue 3(2023) Page Start: 273 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial. Issue 21 (20th July 2021) Authors: Tolaney, Sara M.; Tayob, Nabihah; Dang, Chau; Yardley, Denise A.; Isakoff, Steven J.; Valero, Vicente; Faggen, Meredith; Mulvey, Therese; Bose, Ron; Hu, Jiani; Weckstein, Douglas; Wolff, Antonio C.; Reeder-Hayes, Katherine; Rugo, Hope S.; Ramaswamy, Bhuvaneswari; Zuckerman, Dan; Hart, Lowell; Gad... Journal: Journal of clinical oncology Issue: Volume 39:Issue 21(2021) Page Start: 2375 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗